KDR and melanoma: Furthermore, we found synergistic interaction between cediranib and PLX4720 in non-melanoma BRAFV600E mutant cell lines with expression of KDR/PDGFRα/β family members (S9D Fig), suggesting the combination may be effective broadly across BRAFV600E mutant cancers beyond melanoma.